Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023
pharmafile | November 18, 2019 | News story | Sales and Marketing | Abrilada, FDA, Humira, Pfizer, biosimilar, pharma
Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb), its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,
Pfizer’s therapy is now authorised for use in all approved indications of its reference product, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.
“Comprehensive” data submitted in support of the decision showed that Abrilada demonstrated adequate biosimilarity to Humira, including no meaningful differences in terms of safety, efficacy or immunogenicity in moderate to severe rheumatoid arthritis.
“Biosimilars like Abrilada represent an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions,” remarked Richard Blackburn, Global President, Pfizer Inflammation and Immunology. “Our current portfolio of approved biosimilar products is one of the broadest in the industry and we are proud to offer additional treatment options for patients.”
Pfizer confirmed that the intended launch date of the drug in the US is set for 2023.
Matt Fellows
Related Content
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …